Eli Lilly and Company $LLY Shares Sold by Ibex Wealth Advisors

Ibex Wealth Advisors trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 30.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,433 shares of the company’s stock after selling 3,775 shares during the quarter. Ibex Wealth Advisors’ holdings in Eli Lilly and Company were worth $9,757,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Coastal Bridge Advisors LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $2,959,000. Birinyi Associates Inc. lifted its position in Eli Lilly and Company by 32.6% in the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after buying an additional 359 shares during the last quarter. Bernicke Wealth Management Ltd. bought a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $5,001,000. Mosaic Family Wealth Partners LLC boosted its stake in Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after buying an additional 1,430 shares in the last quarter. Finally, Heritage Investors Management Corp boosted its stake in Eli Lilly and Company by 6.5% in the third quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock worth $13,624,000 after buying an additional 718 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 1.2%

LLY stock traded up $16.77 during midday trading on Friday, hitting $1,444.05. The company had a trading volume of 2,080,606 shares, compared to its average volume of 3,003,279. The stock has a market cap of $1.36 trillion, a price-to-earnings ratio of 46.87, a PEG ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,460.00. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock’s 50 day moving average price is $1,242.25 and its 200 day moving average price is $1,110.30.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue was up 38.6% on a year-over-year basis. During the same quarter last year, the business earned $7.02 earnings per share. As a group, equities research analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Leerink Partners boosted their price objective on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a report on Wednesday, October 21st. Truist Financial reaffirmed a “buy” rating and issued a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a report on Monday, October 26th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,416.64.

Read Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company News Summary

These are some of the LLY news items that stood out recently:

  • Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
  • Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
  • Neutral Sentiment: Lilly is advancing an early-stage ALS drug study, but investors are still waiting for clinical data, so the update does not yet establish whether the treatment will succeed. Eli Lilly advances early ALS drug study

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.